Alexander P Hoffmann1, Michael C Honigberg2,3,4. 1. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. 2. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA. mhonigberg@mgh.harvard.edu. 3. Cardiovascular Research Center, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA, 02114, USA. mhonigberg@mgh.harvard.edu. 4. Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, MA, Boston, 02114, USA. mhonigberg@mgh.harvard.edu.
Abstract
PURPOSE OF REVIEW: Prediabetes, or dysglycemia in the absence of diabetes, is a prevalent condition typically defined by a glycated hemoglobin (HgbA1c) of 5.7- < 6.5%. This article reviews current contemporary data examining the association between prediabetes and cardiovascular disease (CVD) as well as HgbA1c as a continuous measure of cardiovascular risk across the glycemic spectrum. RECENT FINDINGS: Dysglycemia in the prediabetic range is associated with an increased risk of both subclinical and clinical CVD, including atherosclerotic CVD, chronic kidney disease, and heart failure. Several recent large, prospective studies demonstrate roughly linear risk with increasing HgbA1c, even below the threshold for prediabetes. "High-risk" patients with prediabetes have similar CVD risk as those with diabetes. HgbA1c below the threshold for diabetes stratifies CVD risk. Use of HgbA1c as a continuous measure, rather than simply dichotomized, may inform current and future prevention strategies. Given the high population attributable risk associated with prediabetes, targeted prevention strategies in this population warrant dedicated study.
PURPOSE OF REVIEW: Prediabetes, or dysglycemia in the absence of diabetes, is a prevalent condition typically defined by a glycated hemoglobin (HgbA1c) of 5.7- < 6.5%. This article reviews current contemporary data examining the association between prediabetes and cardiovascular disease (CVD) as well as HgbA1c as a continuous measure of cardiovascular risk across the glycemic spectrum. RECENT FINDINGS: Dysglycemia in the prediabetic range is associated with an increased risk of both subclinical and clinical CVD, including atherosclerotic CVD, chronic kidney disease, and heart failure. Several recent large, prospective studies demonstrate roughly linear risk with increasing HgbA1c, even below the threshold for prediabetes. "High-risk" patients with prediabetes have similar CVD risk as those with diabetes. HgbA1c below the threshold for diabetes stratifies CVD risk. Use of HgbA1c as a continuous measure, rather than simply dichotomized, may inform current and future prevention strategies. Given the high population attributable risk associated with prediabetes, targeted prevention strategies in this population warrant dedicated study.
Authors: Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir Journal: N Engl J Med Date: 2017-04-13 Impact factor: 91.245
Authors: Aidin Rawshani; Araz Rawshani; Stefan Franzén; Naveed Sattar; Björn Eliasson; Ann-Marie Svensson; Björn Zethelius; Mervete Miftaraj; Darren K McGuire; Annika Rosengren; Soffia Gudbjörnsdottir Journal: N Engl J Med Date: 2018-08-16 Impact factor: 91.245
Authors: Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng Journal: Lancet Date: 2004 Sep 11-17 Impact factor: 79.321
Authors: Anoop Dinesh Shah; Claudia Langenberg; Eleni Rapsomaniki; Spiros Denaxas; Mar Pujades-Rodriguez; Chris P Gale; John Deanfield; Liam Smeeth; Adam Timmis; Harry Hemingway Journal: Lancet Date: 2015-02-26 Impact factor: 79.321
Authors: Kai McKeever Bullard; Sharon H Saydah; Giuseppina Imperatore; Catherine C Cowie; Edward W Gregg; Linda S Geiss; Yiling J Cheng; Deborah B Rolka; Desmond E Williams; Carl J Caspersen Journal: Diabetes Care Date: 2013-04-19 Impact factor: 19.112
Authors: David A McAllister; Stephanie H Read; Jan Kerssens; Shona Livingstone; Stuart McGurnaghan; Pardeep Jhund; John Petrie; Naveed Sattar; Colin Fischbacher; Soren Lund Kristensen; John McMurray; Helen M Colhoun; Sarah H Wild Journal: Circulation Date: 2018-12-11 Impact factor: 29.690